Thomas Teisseyre sold $1,610 of HYPR
Chief Operating Officer at Hyperfine, Inc.. 2,776 shares at an average of $0.58, traded May 16, 2025, filed May 16, 2025.
Score components
- +20RoleCOO
- 0Trade size$2k at market
- 0Share of holdings soldSold 3.3% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-073807, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 16, 2025 | SOpen-market sale Class A Common Stock | -2,776 | $0.58 | $1,610 | 82,213 | May 16, 2025 |
Related signals
Other insiders at Hyperfine, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | HYPRsell Hyperfine, Inc. | Thomas Teisseyre Chief Operating Officer | $1,517 1,405 shares | -0% | |
| 20Weak | HYPRsell Hyperfine, Inc. | Thomas Teisseyre Chief Operating Officer | $1,531 1,151 shares | -0% | |
| 20Weak | HYPRsell Hyperfine, Inc. | Thomas Teisseyre Chief Operating Officer | $3,884 3,237 shares | -4% | |
| 20Weak | HYPRsell Hyperfine, Inc. | Thomas Teisseyre Chief Operating Officer | $2,380 2,800 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.